Fig. 1: Kaplan–Meier estimates of overall survival according to age.
From: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
The curves illustrate the prognostic relationship of age (<75 and ≥75 years) with overall survival in patients receiving sorafenib for HCC.
